Eve M. Walton: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Antiviral activity of hop constituents against a series of DNA and RNA viruses

Victor E Buckwold, Richard J.H Wilson, Aysegul Nalca, Brigitte B Beer, Thomas G Voss, Jim A Turpin, Robert W Buckheit III, Jiayi Wei, Michelle Wenzel-Mathers, Eve M Walton, Robert J Smith, Melanie Pal

Journal:

Antiviral Research

Year:

2004

Language:

english

File:

PDF, 83 KB

english, 2004

2

Ca+ + antagonists distinguish different requirements for cAMP-mediated gene expression in the cellular slime mold, Dictyostelium discoideum

Daphne D. Blumberg, Joann F. Comer, Eve M. Walton

Journal:

Differentiation

Year:

1989

Language:

english

File:

PDF, 955 KB

english, 1989

3

Transoral Resection of Spinal Cord Tumors and Posterior Cervical Spine Stabilization

Phyllis G. Walton, Eve L. Broughton

Journal:

Year:

1997

Language:

english

File:

PDF, 5.35 MB

english, 1997

4

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Yap, T. A., Walton, M. I., Grimshaw, K. M., te Poele, R. H., Eve, P. D., Valenti, M. R., de Haven Brandon, A. K., Martins, V., Zetterlund, A., Heaton, S. P., Heinzmann, K., Jones, P. S., Feltell, R. E

Journal:

Clinical Cancer Research

Year:

2012

Language:

english

File:

PDF, 1.46 MB

english, 2012

5

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, Aherne, G. W

Journal:

Journal of Medicinal Chemistry

Year:

2012

Language:

english

File:

PDF, 1.84 MB

english, 2012

6

CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors

Anderson, V. E., Walton, M. I., Eve, P. D., Boxall, K. J., Antoni, L., Caldwell, J. J., Aherne, W., Pearl, L. H., Oliver, A. W., Collins, I., Garrett, M. D.

Journal:

Cancer Research

Year:

2011

Language:

english

File:

PDF, 1.07 MB

english, 2011

7

exploring drug users' illness representations of hiv, hepatitis b and hepatitis c using repertory grids

Walton, Andrea Jennifer, Eves, Frank

Journal:

Psychology and Health

Year:

2001

Language:

english

File:

PDF, 852 KB

english, 2001

8

Weed Risk Assessment of Plant Imports to Australia: Policy and Process

Steinke, Eve, Walton, Craig

Journal:

Australasian Journal of Environmental Management

Year:

1999

Language:

english

File:

PDF, 675 KB

english, 1999

9

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., De Haven Brandon, A. K., Box, G., Hallsworth, A., Smith, E. L., Boxall, K. J., Lainchbury, M., Matthews, T. P., Jamin, Y., Robinson, S. P., Aherne

Journal:

Clinical Cancer Research

Year:

2012

Language:

english

File:

PDF, 1.09 MB

english, 2012

10

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Yap, T. A., Walton, M. I., Hunter, L.-J. K., Valenti, M., de Haven Brandon, A., Eve, P. D., Ruddle, R., Heaton, S. P., Henley, A., Pickard, L., Vijayaraghavan, G., Caldwell, J. J., Thompson, N. T., Ah

Journal:

Molecular Cancer Therapeutics

Year:

2011

Language:

english

File:

PDF, 1.29 MB

english, 2011

11

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Walton, M. I., Eve, P. D., Hayes, A., Valenti, M., De Haven Brandon, A., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., Williams, D. H., Reader, J. C., Collins, I., Garrett, M.

Journal:

Molecular Cancer Therapeutics

Year:

2010

Language:

english

File:

PDF, 1.26 MB

english, 2010

12

Multi-parameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Osborne, James D, Matthews, Thomas Peter, McHardy, Tatiana, Proisy, Nicolas, Cheung, Kwai-Ming Jack, Lainchbury, Michael, Brown, Nathan, Walton, Michael I, Eve, Paul D, Boxall, Katherine J., Hayes, An

Journal:

Journal of Medicinal Chemistry

Year:

2016

Language:

english

File:

PDF, 1.79 MB

english, 2016